Incendia Therapeutics is creating a novel class of anti-cancer therapies to reprogram the tumor microenvironment (TME). Cancer cells manipulate their microenvironment to enhance their own survival. Incendia’s approach is to attack the structural and biochemical underpinnings of the TME to facilitate host immune cells to reach their targets. Incendia’s lead program is a physical barrier disruptor, PRTH-101 in phase I clinical trials. PRTH-101 is a monoclonal antibody that binds to and blocks the collagen receptor DDR1, disrupting collagen fiber alignment in cancer TMEs creating gaps in the barrier.

Incendia Therapeutics

Founded: 2019
Location: Boston, MA
Employee range: 1-50
Clinical stage: Clin1b
Therapy area: solid tumors
Drug types: ONC
Lead product: PRTH-101
Funding: 10-100M

Drug notes:

About:

Jobs: